124 related articles for article (PubMed ID: 37640197)
1. Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC.
Wang J; Zhang T; Li P; Gai J; Chen S; Espinoza G; Kung HC; Zhang R; Fujiwara K; Fu J; Yu J; Zheng L
Cancer Lett; 2023 Oct; 573():216366. PubMed ID: 37640197
[TBL] [Abstract][Full Text] [Related]
2. Direct identification of HLA class I and class II-restricted T cell epitopes in pancreatic cancer tissues by mass spectrometry.
Fujiwara K; Shao Y; Niu N; Zhang T; Herbst B; Henderson M; Muth S; Zhang P; Zheng L
J Hematol Oncol; 2022 Oct; 15(1):154. PubMed ID: 36284347
[TBL] [Abstract][Full Text] [Related]
3. Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics.
Ade CM; Sporn MJ; Das S; Yu Z; Hanada KI; Qi YA; Maity T; Zhang X; Guha U; Andresson T; Yang JC
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37758652
[TBL] [Abstract][Full Text] [Related]
4. Antigen/HLA-agnostic strategies for Characterizing Tumor-responsive T cell receptors in PDAC patients via single-cell sequencing and autologous organoid application.
Wang X; Dai Z; Lin X; Zou X; Wang R; Tasiheng Y; Yan Y; Ma M; Chen Y; Cheng H; Liu C; Yu X
Cancer Lett; 2024 Apr; 588():216741. PubMed ID: 38395378
[TBL] [Abstract][Full Text] [Related]
5. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
6. MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy.
Baleeiro RB; Bouwens CJ; Liu P; Di Gioia C; Dunmall LSC; Nagano A; Gangeswaran R; Chelala C; Kocher HM; Lemoine NR; Wang Y
Oncoimmunology; 2022; 11(1):2080329. PubMed ID: 35655709
[TBL] [Abstract][Full Text] [Related]
7. ITGA2, LAMB3, and LAMC2 may be the potential therapeutic targets in pancreatic ductal adenocarcinoma: an integrated bioinformatics analysis.
Islam S; Kitagawa T; Baron B; Abiko Y; Chiba I; Kuramitsu Y
Sci Rep; 2021 May; 11(1):10563. PubMed ID: 34007003
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reaction.
Tanemura M; Miyoshi E; Nagano H; Eguchi H; Matsunami K; Taniyama K; Hatanaka N; Akamatsu H; Mori M; Doki Y
World J Gastroenterol; 2015 Oct; 21(40):11396-410. PubMed ID: 26523105
[TBL] [Abstract][Full Text] [Related]
9. Global analysis of HLA-A2 restricted MAGE-A3 tumor antigen epitopes and corresponding TCRs in non-small cell lung cancer.
Zhang B; Ren Z; Zhao J; Zhu Y; Huang B; Xiao C; Zhang Y; Deng J; Mao L; Tang L; Lan D; Gao L; Zhang H; Chen G; Luo OJ
Theranostics; 2023; 13(13):4449-4468. PubMed ID: 37649599
[No Abstract] [Full Text] [Related]
10. Intratumoral T-cell receptor repertoire composition predicts overall survival in patients with pancreatic ductal adenocarcinoma.
Pothuri VS; Hogg GD; Conant L; Borcherding N; James CA; Mudd J; Williams G; Seo YD; Hawkins WG; Pillarisetty VG; DeNardo DG; Fields RC
Oncoimmunology; 2024; 13(1):2320411. PubMed ID: 38504847
[TBL] [Abstract][Full Text] [Related]
11. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
Abate-Daga D; Speiser DE; Chinnasamy N; Zheng Z; Xu H; Feldman SA; Rosenberg SA; Morgan RA
PLoS One; 2014; 9(3):e93321. PubMed ID: 24681846
[TBL] [Abstract][Full Text] [Related]
12. Tumor-Infiltrating B- and T-Cell Repertoire in Pancreatic Cancer Associated With Host and Tumor Features.
Pineda S; López de Maturana E; Yu K; Ravoor A; Wood I; Malats N; Sirota M
Front Immunol; 2021; 12():730746. PubMed ID: 34630409
[TBL] [Abstract][Full Text] [Related]
13. LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth.
Erice O; Narayanan S; Feliu I; Entrialgo-Cadierno R; Malinova A; Vicentini C; Guruceaga E; Delfino P; Trajkovic-Arsic M; Moreno H; Valencia K; Blanco E; Macaya I; Öhlund D; Khatri P; Lecanda F; Scarpa A; Siveke JT; Corbo V; Ponz-Sarvise M; Vicent S
Clin Cancer Res; 2023 Mar; 29(6):1137-1154. PubMed ID: 36607777
[TBL] [Abstract][Full Text] [Related]
14. Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers.
Bradley SD; Talukder AH; Lai I; Davis R; Alvarez H; Tiriac H; Zhang M; Chiu Y; Melendez B; Jackson KR; Katailiha A; Sonnemann HM; Li F; Kang Y; Qiao N; Pan BF; Lorenzi PL; Hurd M; Mittendorf EA; Peterson CB; Javle M; Bristow C; Kim M; Tuveson DA; Hawke D; Kopetz S; Wolff RA; Hwu P; Maitra A; Roszik J; Yee C; Lizée G
Nat Commun; 2020 Oct; 11(1):5332. PubMed ID: 33087697
[TBL] [Abstract][Full Text] [Related]
15. Antigen identification for HLA class I- and HLA class II-restricted T cell receptors using cytokine-capturing antigen-presenting cells.
Lee MN; Meyerson M
Sci Immunol; 2021 Jan; 6(55):. PubMed ID: 33483338
[TBL] [Abstract][Full Text] [Related]
16. Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression.
Cheung PF; Yang J; Fang R; Borgers A; Krengel K; Stoffel A; Althoff K; Yip CW; Siu EHL; Ng LWC; Lang KS; Cham LB; Engel DR; Soun C; Cima I; Scheffler B; Striefler JK; Sinn M; Bahra M; Pelzer U; Oettle H; Markus P; Smeets EMM; Aarntzen EHJG; Savvatakis K; Liffers ST; Lueong SS; Neander C; Bazarna A; Zhang X; Paschen A; Crawford HC; Chan AWH; Cheung ST; Siveke JT
Nat Commun; 2022 Jan; 13(1):156. PubMed ID: 35013174
[TBL] [Abstract][Full Text] [Related]
17. NDRG1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting ATG9A-dependent degradation of MHC-1.
Zhang Z; Song B; Wei H; Liu Y; Zhang W; Yang Y; Sun B
Drug Resist Updat; 2024 Mar; 73():101040. PubMed ID: 38228036
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of laminin-5 gamma-2 promotes tumorigenesis of pancreatic ductal adenocarcinoma through EGFR/ERK1/2/AKT/mTOR cascade.
Kirtonia A; Pandey AK; Ramachandran B; Mishra DP; Dawson DW; Sethi G; Ganesan TS; Koeffler HP; Garg M
Cell Mol Life Sci; 2022 Jun; 79(7):362. PubMed ID: 35699794
[TBL] [Abstract][Full Text] [Related]
19. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
[TBL] [Abstract][Full Text] [Related]
20. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
